Angiotech's Corporate Partner, Boston Scientific, Announces Japanese Approval for the TAXUS® Express2(TM) Stent System
Share:
VANCOUVER, April 3 - Angiotech Pharmaceuticals, Inc. (NASDAQ:ANPI)(NASDAQ:TSX:)(NASDAQ:ANP), a global specialty pharmaceutical and medical device company, along with its corporate partner, Boston Scientific Corporation (NYSE:BSX), announced today that Boston Scientific has received approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) to market its TAXUS® Express2(TM) paclitaxel-eluting coronary stent system in Japan. Boston Scientific plans to launch the product upon receipt of reimbursement approval.
"We are pleased that the proven technology of the TAXUS Express2 stent is now available to Japanese physicians, which will help improve the quality of life for so many patients," said Dr. William Hunter, President and CEO of Angiotech.
Angiotech Pharmaceuticals, Inc. is a global specialty pharmaceutical and medical device company with 17 facilities in 6 countries and over 1,500 dedicated employees. Angiotech discovers, develops and markets innovative treatment solutions for diseases or complications associated with medical device implants, surgical interventions and acute injury. To find out more about Angiotech (NASDAQ:ANPI)(NASDAQ:TSX:)(NASDAQ:ANP), please visit our website at www.angiotech.com.
Source: Angiotech Pharmaceuticals, Inc.
